The Relative Value of Anti-Obesity Medications Compared to Similar Therapies.

Nina KimJoaquin EstradaIsabella ChowAleksandrina RusevaAbhilasha RamasamyChakkarin BurudpakdeeChristopher M Blanchette

Published in: ClinicoEconomics and outcomes research : CEOR (2023)

Compared to four therapeutic analogues, obesity represented the highest economic burden and was associated with more comorbidities. AOMs provide greater cost savings compared to selected analogues. However, AOMs have limited formulary coverage. Improved coverage of AOMs may increase access to these treatments and may help address the clinical and economic burden associated with obesity and its comorbidities.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
high fat diet induced
type diabetes
weight gain
molecular docking
adipose tissue
affordable care act
healthcare
body mass index
molecular dynamics simulations